This is an aggregated industry headline. Read the full story at BioPharma Dive →
cAMPfield lands $180M to build gut disease drug
The biotech is advancing an anti-inflammatory drug that originated with vTv for inflammatory bowel diseases, leaning on a better side effect profile.
By BioPharma Dive
· Jun 18, 2026
· via BioPharma Dive
Image: BioPharma Dive
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineBioPharma Dive
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Pfizer's CFO Dave Denton will officially depart in August, leaving SVP of finance Cecile Guegan to take up his…
The WeekFierceBiotech ↗
Zoll Medical, the maker of devices and software focused on cardiopulmonary and respiratory conditions, was sla…
The WeekBriefing
PwC says pharma and life sciences deals topped $65B in Q1 2026, led by big-ticket buys from Sun Pharma and GSK…